Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1931191 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL2567369 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL12344817 | 0.80 | KDM4E (0.55) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL1932542 | 0.79 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL2172995 | 0.78 | KDM4E (0.51) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL27839232 | 0.76 | KDM4E (0.49) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL779982 | 0.74 | KDM4E (0.73) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL1931358 | 0.73 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL1931109 | 0.72 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EHSD17B10TARBP2 | |
| SCHEMBL3775173 | 0.71 | PPARG (0.47) | ALDH1A1PPARGPPARAIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-2185550-B1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2185550-B1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| CN-101939317-A | Substituted aryl oxazoles and their use | BAYER HEALTHCARE AG | 2011-01-05 | — | — | CN | disclosed |
| WO-2009015776-A1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | ALDH1A1 371/4885LMNA 2430/4885KDM4E 1724/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | ALDH1A1 555/4885LMNA 1142/4885KDM4E 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.